Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition
Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.
You may also be interested in...
Albireo Sets Sights On Rare Disease Model
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity
Elobixibat demonstrated ability to reduce LDL cholesterol but is being discontinued in NASH due to its unspectacular overall profile. The firm is staying focused on odevixibat, which could be best-in-class for pediatric liver indications, analysts say.
NASH Companies Take The Stage At AASLD
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.